{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=lapatinib+ditosylate&page=3", "query": { "intervention": "lapatinib ditosylate", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 181, "total_pages": 19, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=lapatinib+ditosylate&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=lapatinib+ditosylate&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-06T20:47:27.913Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00437073", "title": "Brain Metastases In ErbB2-Positive Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms, Breast" ], "interventions": [ { "name": "capecitabine", "type": "DRUG" }, { "name": "topotecan", "type": "DRUG" }, { "name": "lapatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2007-05", "completion_date": "2010-02", "has_results": true, "last_update_posted_date": "2015-10-15", "last_synced_at": "2026-10-06T20:47:27.913Z", "location_count": 13, "location_summary": "Washington D.C., District of Columbia • Indianapolis, Indiana • Sioux City, Iowa + 10 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Sioux City", "state": "Iowa" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00437073" }, { "nct_id": "NCT00495872", "title": "Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "Dasatinib", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Lapatinib", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" }, { "name": "Sunitinib", "type": "DRUG" }, { "name": "Valproic Acid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 204, "start_date": "2007-06", "completion_date": null, "has_results": false, "last_update_posted_date": "2012-10-18", "last_synced_at": "2026-10-06T20:47:27.913Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00495872" }, { "nct_id": "NCT01827163", "title": "Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER2-Positive Early Stage Breast Cancer" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Lapatinib", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2013-04", "completion_date": "2019-01", "has_results": true, "last_update_posted_date": "2019-12-18", "last_synced_at": "2026-10-06T20:47:27.913Z", "location_count": 4, "location_summary": "Basking Ridge, New Jersey • Commack, New York • New York, New York + 1 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Rockville Centre", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01827163" }, { "nct_id": "NCT00470704", "title": "Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Lapatinib", "type": "DRUG" }, { "name": "Herceptin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nancy Lin, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 87, "start_date": "2007-05-14", "completion_date": "2024-08-20", "has_results": true, "last_update_posted_date": "2024-12-19", "last_synced_at": "2026-10-06T20:47:27.913Z", "location_count": 9, "location_summary": "Birmingham, Alabama • Chicago, Illinois • Boston, Massachusetts + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00470704" }, { "nct_id": "NCT00424255", "title": "Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neoplasms, Head and Neck" ], "interventions": [ { "name": "Lapatinib", "type": "DRUG" }, { "name": "Chemoradiation", "type": "RADIATION" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "RADIATION", "OTHER" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 688, "start_date": "2006-12", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2014-07-18", "last_synced_at": "2026-10-06T20:47:27.913Z", "location_count": 5, "location_summary": "Springfield, Illinois • St Louis, Missouri • New York, New York + 2 more", "locations": [ { "city": "Springfield", "state": "Illinois" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Lubbock", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00424255" }, { "nct_id": "NCT01873833", "title": "Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER2-positive Breast Cancer", "Recurrent Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "capecitabine", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "lapatinib ditosylate", "type": "DRUG" }, { "name": "trastuzumab", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 10, "start_date": "2013-07-29", "completion_date": "2021-03-02", "has_results": true, "last_update_posted_date": "2023-10-05", "last_synced_at": "2026-10-06T20:47:27.913Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01873833" }, { "nct_id": "NCT01934894", "title": "Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer With Intracranial Metastases" ], "interventions": [ { "name": "cabazitaxel", "type": "DRUG" }, { "name": "lapatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2014-05", "completion_date": "2017-04", "has_results": true, "last_update_posted_date": "2017-07-02", "last_synced_at": "2026-10-06T20:47:27.913Z", "location_count": 4, "location_summary": "Fort Myers, Florida • St. Petersburg, Florida • Cincinnati, Ohio + 1 more", "locations": [ { "city": "Fort Myers", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01934894" }, { "nct_id": "NCT00263588", "title": "Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasms, Breast" ], "interventions": [ { "name": "lapatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 242, "start_date": "2005-12-02", "completion_date": "2018-03-15", "has_results": true, "last_update_posted_date": "2019-12-12", "last_synced_at": "2026-10-06T20:47:27.913Z", "location_count": 28, "location_summary": "San Francisco, California • Vallejo, California • Denver, Colorado + 22 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Vallejo", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boca Raton", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00263588" }, { "nct_id": "NCT00770809", "title": "Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Male Breast Carcinoma", "Stage IIA Breast Cancer AJCC v6 and v7", "Stage IIB Breast Cancer AJCC v6 and v7", "Stage IIIA Breast Cancer AJCC v7", "Stage IIIB Breast Cancer AJCC v7", "Stage IIIC Breast Cancer AJCC v7" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lapatinib Ditosylate", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 305, "start_date": "2009-02-24", "completion_date": "2024-02-15", "has_results": true, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-10-06T20:47:27.913Z", "location_count": 317, "location_summary": "Tucson, Arizona • Fort Smith, Arkansas • Burbank, California + 222 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Burbank", "state": "California" }, { "city": "Castro Valley", "state": "California" }, { "city": "Castro Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00770809" }, { "nct_id": "NCT00103194", "title": "Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Prostate Cancer", "Stage I Prostate Cancer", "Stage IIA Prostate Cancer", "Stage IIB Prostate Cancer", "Stage III Prostate Cancer" ], "interventions": [ { "name": "lapatinib ditosylate", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 49, "start_date": "2005-09", "completion_date": "2013-06", "has_results": true, "last_update_posted_date": "2014-09-30", "last_synced_at": "2026-10-06T20:47:27.913Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00103194" } ] }